PDCD1 and melanoma: The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD1-blocking antibody, has been used in a phase 2–3, global, double-blind, randomized trial to patients with previously untreated metastatic or unresectable melanoma.The median progression-free survival was 10.1 months with relatlimab-nivolumab as compared with 4.6 months with nivolumab (hazard ratio for progression or death, 0.75; P = 0.006).